Study of rhTPO to mobilize stem cells for transplant in acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if rhTPO (a protein that boosts platelet production) can help collect enough stem cells for your own stem cell transplant. It is for people with acute leukemia who are in remission with no detectable cancer cells left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have acute leukemia that is in complete remission with no minimal residual disease (no cancer cells found by sensitive tests).
- You are generally well enough to undergo stem cell collection (ECOG score less than 2).
- You do not have active infections or severe organ problems.
- You have not had a blood clot in the past or severe allergic reaction to rhTPO.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial tests whether adding a platelet-boosting medicine (rhTPO) to a standard immune-suppressing drug (cyclosporine) works better than cyclosporine alone for people with aplastic anemia who need regular blood transfusions. The goal is to improve blood counts and reduce the need for transfusions.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Hear when a new Hematopoietic Stem Cell Mobilization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.